Eris Lifesciences (ERIS) investor relations material

Executive summary

• Q1 FY27 consolidated revenue grew 13% year-over-year to ₹873 crore, with PAT up 14.5% to ₹143 crore; unaudited results were approved with unmodified opinions.

• Domestic Branded Formulations (DBF) segment achieved 14.2% growth, with seven out of ten therapies posting double-digit growth rates.

• EBITDA margin was 34%-35%, influenced by gross margin movement and higher biologics share.

• Insulin and semaglutide franchises delivered strong growth, with semaglutide achieving #1 rank in generic market by unit share.

• The group operates primarily in pharmaceuticals, with recent acquisitions and ongoing restructuring activities.

Financial highlights

• Consolidated revenue from operations for Q1 FY27 was ₹873.25 crore, up from ₹771.56 crore year-over-year.

• Consolidated net profit after tax for the quarter was ₹143.32 crore, compared to ₹125.10 crore in Q1 FY26.

• EBITDA margin at 34%-35%; operating cash flow at 77% of EBITDA; Q1 capex was ₹88 crore.

• EPS for the quarter was ₹10.28; effective book tax rate at 20%, down from 22.5% last year.

• PAT margin at 16.4%, up from 16.2% year-over-year.

Outlook and guidance

• Full-year revenue expected to be 300 basis points above market growth, targeting 14% if the market is at 11%.

• Priorities include regaining momentum in OAD and Cardiac therapies, commercializing Eris Bionxt, and entering the insulin analogs market.

• Board declared an interim dividend of ₹7.21 per equity share for FY27.

• No major acquisitions planned; focus remains on manufacturing investments and organic growth.

• Swiss Parenterals aims to complete EU CAPA actions by Dec 2026 and commission Unit-3 in FY28.